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ABBREVIATION 
 
TED- Thyroid Eye disease 
TPO- Thyroid peroxidase 
MIT - Mono iodo tyrosine 
DIT- Di Iodo Tyrosine 
TBG- Thyroid Binding Globulin 
IGF- 1-Insulin Like Growth Factor-1 
TSHR-Thyroid Stimulating Hormone Receptor 
GAG- Glycosaminoglycans 
IOP- Intraocular Pressure 
SR- LPS-Superior Rectus-Levator Palpebrae Superioris complex 
IR- Inferior Rectus 
MR- Medial Rectus 
SO- Superior Oblique 
EOM- Extraocular Muscles 
VA- Visual Acuity 
CAS- Clinical Activity score 
IV MP- Intravenous Methyl Prednisolone 
BSV- Binocular single vision 
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INTRODUCTION 
 
Thyroid eye disease (TED) also known as Graves Orbitopathy, is 
typically self-limiting autoimmune process associated with dysthyroid 
status. Incidence of TED is 90% in graves disease,3% in Hashimoto’s 
Thyroiditis,1% in primary  Hypothyroidism, and 6% in Euthyroid status 
and at least 50% of these patients develop clinically evident symptomatic 
TED. The patients may present as mild disease to severe irreversible 
disease. In 5-10% of patients vision loss occurs due to corneal 
decompensation or optic nerve compression.TED affects women 2.5-6 
times more frequently than men, in older age female : male ratio decreases. 
The peak incidence is in second to fifth decade, severity increases with 
older than 50 years. Smoking is strongly associated with TED due to 
generalized stimulation of autoimmune disease and effect of hypoxia on 
orbital fibroblast. Diabetics tends to have more severity in TED. 
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HISTORY 
 
 Thyroid-related orbitopathy has been recognized by the medical 
community since 200 years. Caleb Parry showed the association between 
eyeball enlargement and goiter in the year 1786 .In 1835, Robert J Graves 
described the symptom complex of thyroid enlargement, protrusion of eyes 
and palpitation. Adolph von Basedow also described these features in the 
same period  
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PHYSIOLOGY OF THYROID HORMONE 
 
Secretion of thyroid hormones Approximately 100 µg of thyroid 
hormones is secreted each day, mostly in the form of T4 with about 10% 
as T3. Eighty percent of the T4 undergoes peripheral conversion to the 
more active T3 in the liver and kidney (T3 is ten times more active than 
T4) or to reverse T3 (rT3) that has little or no biological activity. Excess 
iodine given to a person with normal thyroid gland activity leads to an  
initial reduction in organification and hormone synthesis and secretion, the 
Wolff-Chaikoff effect. ‘Escape’ from this inhibition, generally occurs after 
several days. 
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Uptake and organification of iodine by the thyroid gland 
1. Active iodide uptake. (I-) in exchange for Na+. 
2. Iodide discharged from the follicular cell by competing ions such as 
perchlorate, bromide or chlorate. 
3. Iodide uptake is stimulated by TSH (the main control point for 
hormone synthesis).  
4. TPO causes Oxidation of iodide by hydrogen peroxide (H2O2) to 
form active iodine.  
5. Active transport of iodine across the apical surface of the follicular 
cell. 
6. Formation of mono- and diiodotyrosines (MIT and DIT) by 
incorporation of active iodine into thyroglobulin molecule. 
7. Uptake of the thyroglobulin into the lumen of the follicle  
8. About 1% of stored colloid is removed each day. When the gland is 
very active this may rise to nearly100% and colloid stores are 
depleted. 
 
THYROID HORMONE TRANSPORT: 
 
Over 99% circulating thyroid hormones are bound to plasma 
proteins of which about 70% is bound to TBG, 10–15% to transthyretin 
13 
and 20-15% to albumin. Only a tiny fraction is in the ‘free’ form. 
Comparison of the serum concentrations of T4 and T3 
 
T4 T3 
Serum concentration T3 T4 
Total 100nmol/l 2nmol/l 
Free 20pmol/l 5pmol/l 
 
Serum half lives: T4 — 7 days, • T3 — 1 day, rT3 — 4 hours. 
 
 
FUNCTIONS OF THYROID HORMONE: 
 
Every cell in the body is acted upon by thyronine. increase in basal 
metabolic rate, regulation of long bone growth in synergy with growth 
hormone and neuronal maturation, affects protein synthesis, increase the 
body’s sensitive response to catecholamines by permissiveness. Hormones 
regulate protein, carbohydrate and fat metabolism. Thyroid hormones 
helps in heat generation. 
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ANATOMY OF ORBIT 
 
The complex of neurosensory, vascular, motor, and secretory 
structures within the orbit are confined to 30 cm
3
, bounded anteriorly by 
the lids, and surrounded by bone, nasal sinuses, intracranial contents, and 
deep facial structures.  The orbit is pyramidal in shape with an overall 
volume of 30 cm
3
, of which the eye constitutes 7 cm
3
. 
  
DIMENSIONS: 
Height of orbital opening - 35mm 
Width of orbital opening - 40mm 
Depth of orbit                 - 40mm 
Interorbital distance        - 25mm 
  
The Orbital walls are composed seven bones: 
Ethmoid, frontal, lacrimal, maxillary, palantine, sphenoid and zygomatic.  
 
THE ORBITAL ROOF: 
 
It is triangular in shape Formed by lesser wing of the sphenoid and 
the orbital part of frontal bones, which may have within it a posterior 
extension of the frontal sinus. Apically, the lesser wing contains the optic 
canal, which is 5 mm to 6 mm in diameter, 10 mm to 12 mm in length and 
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has an axis of 36 to the sagittal plane. Thus, the optic canals are separated 
anteriorly by 3 cm and posteriorly by 2.5 cm.  
 
THE LATERAL WALL:  
 
It is made up of the greater wing of the sphenoid, frontal, and 
zygomatic bones, and is at an angle of 45 to the medial wall. It is 4.5 cm to 
5.0 cm long, and is the strongest orbital wall. Posteriorly, it is separated 
from the roof by the superior orbital fissure and from the floor by the 
inferior orbital fissure.  Laterally, it forms a portion of the temporalis fossa 
and is thinnest at the suture line between the greater wing of the sphenoid 
and the zygomatic bone (where it can be fractured easily at surgery). 
Posteriorly, the inferior orbital fissure communicates with the 
pterygopalatine and infratemporal fossa.  
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THE MEDIAL WALL: 
 
It is the thinnest (0.2 mm to 0.4 mm) and is made up of the 
maxillary, lacrimal, ethmoid, and lesser wing of sphenoid. About 24 mm 
from the anterior lacrimal crest is the anterior ethmoid foramen, and 12 
mm behind this is the posterior ethmoid foramen, which is approximately 6 
mm from the optic canal (described by the mnemonic, “24-12-6”). These 
foramina mark the horizontal level of the cribriform plate at the fronto 
ethmoid suture line. The ethmoid and   frequently the sphenoid and 
maxillary sinuses form part of the medial wall. 
 
 
THE FLOOR: 
 
It is shorter, triangular, and is made up of the maxillary, zygomatic, 
and palatine bones. The infraorbital sulcus originates about 2.5 cm to 3 cm 
from the inferior orbital rim and forms the infraorbital canal halfway along 
its course, which opens on the maxilla at the infraorbital foramen. The 
maxillary and often some of the ethmoid sinuses are immediately adjacent 
to the floor. The thinnest point is medial to the infraorbital sulcus and 
canal, where it can be fractured easily at the time of decompression 
surgery. 
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CONTENTS OF ORBIT: 
 
Eyeball occupying 1/5
th
 of volume, extraocular muscles, LPS and 
mullers muscle of Orbit. Orbital nerves-3, 4, 6
th
 cranial nerve, branches of 
ophthalmic division of  fifth  nerve and branches of maxillary division of 
5
TH
  nerve(infraorbital and zygomatic nerve).Vessels-ophthalmic artery 
and its branches,infraorbital vessels,orbital  branch of middle meningeal 
artery,and superior and inferior ophthalmic vein. Orbital fat, reticular 
tissue and orbital fascia,lacrimal gland and lacrimal sac. 
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PATHOGENESIS 
 
AUTOIMMUNITY:  
 
More than 45 theories has been proposed but still the  pathogenesis 
remains unclear. Interaction between obital fibroblast ,cytokines, immune 
cells, auto antibody, environmental and genetic  factors resulted in increase 
in size of extraocular muscles and  orbital  fat because the orbital tissue 
and thyroid share a common antigen. Thyrotropin receptors (thyroid-
stimulating hormone receptor – TSHR) may play a role as an autoantigen 
in Graves' hyperthyroidism, orbitopathy, and pretibial myxedema. 
Antigens may be thyroglobulin, TSH receptor,IGF-1 receptor, or 
extraocular muscle antigen.  
 
SMOKING: 
Smoking increases the incidence and severity of TED, 5times higher 
risk than those who do not smoke. Dose dependent statistically increase in 
GAG production and adipogenesis. Genetic Predisposition20-60% of 
affected individuals have positive family history of thyroid eye disease. A 
population based study of Danish monozygotic twins showed 30% 
concordance rate. HLA- B8, DR3, andDQA1*0501 haplotypes increases 
susceptibility to the disease and HLA-DR B1*07 offers protection. 
20 
IMMUNOLOGICAL
CELLULAR
MECHANICAL              
autoantibody
activated orbital 
fiboblast
chemokine release
recruitment  of T 
lymphocyte
deposition of  
GAG,adipogenesis 
and  fibroblast  
proliferation
LEHMAN AND COLLEAGUES (PLAUSIBLE PATHWAY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
orbital 
fibroblast
thy 1+
thy 1
ORBITAL FIBROBLAST
It is derived from neural ectoderm whereas other fibroblasts are 
derived from mesenchyme.
can differentiate into adipocytes and myofibroblasts.
 
 
 
 
 
 
 
-
phenotype
60%-differentiated 
into myofibroblast 
like phenotype
40%-differentiates 
into mature 
adiipocytes
:  
 Orbital fibroblast has unique phenotype,
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  that 
T CELL MEDIATED
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B CELL MEDIATED
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RELEASE OF IL
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Both T cell mediated and B cell mediated
 
-2,IFN
5,IL-10 IN LATE STAGE  DISEASE
-ab,IGF-1 R ab
-6 MEDIATED  ACTIVATION OF 
TSH RECEPTOR 
 THROID EYE DISEASE
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CLASSIFICATION 
Werner Classification 
Class Grade Mnemonic Suggestions for Grading 
0 
 
N No physical signs or symptoms 
1 
 
O Signs only 
2 
 
S Soft tissue involvement 
 
0 
 
Absent 
 
A 
 
Minimal 
 
B 
 
Moderate 
 
C 
 
Marked 
3 
 
P Proptosis of 3 mm or more 
 
0 
 
Absent 
 
A 
 
3–4 mm 
 
B 
 
5–7 mm 
 
C 
 
8 mm or more 
4 
 
E Extraocular muscle involvement 
 
0 
 
Absent 
 
A 
 
Limitation of motion at extremes 
of gaze 
 
B 
 
Evident restriction of motion 
 
C 
 
Fixation of globe 
5 
 
C Corneal involvement 
 
0 
 
Absent 
 
A 
 
Punctate lesions 
 
B 
 
Ulceration 
 
C 
 
Necrosis or perforation 
6 
 
S Sight loss (due to optic nerve) 
 
0 
 
Absent 
 
A 
 
20/20–20/60 (<6/6 – 6/18) 
 
B 
 
20/70–20/200 (<6/18 – 6/60) 
 
C 
 
Worse than 20/200 (<6/60) 
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Simplest classification-TYPEI AND TYPE II NON 
INFILTRATIVE OR TYPEI-minimal inflammation and minimal 
restrictive myopathy. INFILTRATIVE OR TYPE II-Significant orbital 
inflammation and restrictive myopathy. 
 
RISK FACTORS: 
 
Male gender, older age, degree of initial thyroid imbalance, 
smoking, Diabetes, acute onset of the disease,  
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BASED ON THE ACTIVITY OF DISEASE: 
 
MILD MODERATE SEVERE 
Adolescent, 
young adult onset 
Lid lag 
Lid retraction 
Lagophthalmos 
Proptosis 
Permanent lid retraction 
Lid lag 
Proptosis 
Soft tissue changes 
Intermittent myopathy 
 
More rapid onset 
Most freq in old age 
group. 
Predominant 
inflammatory 
cicatricial,mass effect 
 
Regress with control of 
hyperthyroidism 
 
Usually settles within 
6months-1yr 
Imaging-
Disproportionate 
proptosis with mild 
EOM enlargement, 
Increase in fat content 
 
Progressive 
exophthalmos 
Soft tissue involvement, 
Progressive 
myopathy 
Optic neuropathy 
 
 
 
ITEDS-INTERNATIONAL THYROID EYE DISEASE GROUP-
has developed VISA-VISION, INFLAMMATION, STRABISMUS, 
APPEARANCE CLASSIFICATION devised by DOLMAN AND 
ROOTMAN based on international working group suggestion. This helps 
direct appropriate management for patients with TED in a logical 
sequence. 
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CLINICAL MANIFESTATIONS 
 
The clinical manifestations of thyroid orbitopathy are mainly due to 
edema inflammation, and fibrotic changes within the soft tissues of the 
orbit.  
 
NATURAL HISTORY: 
During the course of TED, the disease passes through several 
phases. 
1. Dynamic phase of progressive deterioration 
2. Plataeu phase  
3. Improvement 
4. Static/burnt out phase  
 
RUNDLES CURVE 
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Presentation: 
Lid retraction   – 35 - 60 % 
Lid lag               – 40 - 50 % 
Increased IOP   –  30 % 
Proptosis           –  30 % 
Extreme proptosis   –  3 - 7% 
Malignant exophthalmos  –  2- 7 %  
 
LID RETRACTION: 
Most common cause for upper lid retraction is TRO. It may be due 
to Sympathetic overactivity, Fibrosis & contracture of levator / SR 
complex, Tethering of IR causing accentuation of lid retraction in upgaze. 
Greater amount of sclera visible temporally than nasally called temporal 
flare due to fibrosis of lacrimal gland fascia and leavator aponeurosis. 
Lower lid retraction is due to fibrosis of capsulopalpebral fascia.  
 
DIFFERENTIAL DIAGNOSIS: 
Neurological disease, Marcus gunn phenomenon,Midbrain disease 
like Hydrocephalus, Parinauds syndrome, Trauma/aneurysm involving 3
rd
 
nerve, Sympathomimetic drugs, Cirrhosis, Congenital, Post surgical causes 
like ptosis, Post traumatic and idiopathic . 
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RESTRICTIVE MYOPATHY: 
 
EOM Involvement in 30 – 50 % of patients with TRO, tendons will 
be spared. Initially due to inflammation and later fibrosis there may be 
associated restriction of elevation due to IR fibrosis. Diplopia in upgaze is 
the common complaint in these patients. IR > MR > SR-LPS > LR. May 
also mimic superior oblique palsy  
 
IOP IN THYROID ORBITOPATHY:  
 
May be raised in 30 % cases in patients with restrictive 
myopathy.IOP may increase by 4mm Hg in upgaze, IOP >9mm of Hg 
correlates with optic neuropathy. Elevated episcleral venous pressure due 
to obstruction of orbital veins can cause elevation of IOP. 
 
DIFFERENTIAL DIAGNOSIS: 
Idiopathic myositis, pseudotumour, Sarcoid, Wegener’s 
granulomatosis, metastasis to EOM, Carotid-cavernous fistula, Amyloid, 
Collagen vascular diseases. 
 
SOFT TISSUE SIGNS: 
Lid edema and erythema, conjunctival chemosis and caruncular 
edema 
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EXOPHTHALMOS: 
 
TED is the most common cause of both unilateral and bilateral axial 
proptosis in adults. Measurement of 2 mm or more above normal limit 
(20mm) is absolute, relative when compared with other eye and the basal  
reading is kept constant to follow up the patient for comparative study. 
When the pressure within the retrobulbar tissues exceeds the forces 
counteracting proptosis, the rare complication of subluxation of the globe 
anterior to the eyelid may occur. The increased orbital volume is usually 
due to both extraocular muscle and orbital fat expansion, younger patients 
exhibit more of fat involvement and older patients more of muscle. 
 
EXOPHTHALMOMETRY: 
 
Mild          :  21-23mm 
Moderate  :  24-27mm 
Marked     :  28mm or more 
 
EXPOSURE KERATITIS:  
 
It can occur due to Proptosis, inadequate Bell’s phenomenon and 
Superior limbic keratoconjunctivitis can coexist. 
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OPTIC NEUROPATHY: 
 
Incidence < 5 %, but most common cause of blindness. More 
common in males, usually older patients. Compression of optic nerve at 
orbital apex by enlarged extraocular muscle and inflammation of optic 
nerve sheath. It can occur without significant proptosis. 18 % of patients 
may have VA 6/6 to 6/9, abnormal disc (swollen / pale) in 52 %, Visual 
field defects in 66% and Colour Vision may not be reliable (esp. Ishihara). 
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EVALUATION 
 
Evaluation of patients presenting initially or referred from 
endocrinology department as a known case of hypo/hyperthyroidism, 
detailed history taking with regard to disease onset, duration and rate of 
progression of the disease, history of  smoking  and history pertaining to 
ocular symptoms like pain, redness, foreign body sensation, photophobia, 
defective vision, double vision were noted. Complete ophthalmology 
workup included Visual acuity, slit lamp examination of  anterior segment, 
pupillary reaction, extraocular movements, differential intraocular  
pressure measurement, Hertels Exophthalmometry, schimers test ,fields, 
colour  vision, diplopia charting, fundus examination, forced duction test.  
 
 
SEROLOGICAL TEST:  
 
Serum level-IL6, HS-CRP, RBS, Free T3, T4, TSH (stimulation of 
IGFR-1R with IGF-1 or immunoglobulin G shown to increase IL 6, 
fibroblast causes increased expression of TSHR which resulted in 
upregulation of  TNF-α and IL-6.) 
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IMAGING: 
CT SCAN ORBIT-axial and coronal view-more sensitive than MRI 
in identifying extraocular muscle enlargement. CT Findings: Tendon 
sparing muscle belly enlargement, apparent increase in  orbital fat volume, 
and apical crowding of optic nerve.  
 
B SCAN (Orbital ultrasound OTI Scan -1000 with ultrasound probe 
of 7.5-10 MHZ) provides topographic information of extraocular muscles 
Medium gain setting with patient fixating towards the muscle being 
examined, longitudinal mode with probe placed opposite to muscle. 
Internal structure & reflectivity evaluated in anterior 1/3
rd
 -1/2 of 
muscle.Double peaked sheath spikes indicates that perpendicularity is 
achieved. The findings are -Tendon sparing extraocular muscle 
enlargement, Heterogenous irregular echoes, swelling of orbital fat and lid 
tissues, Enlargement of lacrimal gland and Optic nervehead thickening. A 
scan -moderate to low intense spikes due to large interfaces with in the 
muscle due to edema and inflammatory cells. Bilateral asymmetrical 
muscle thickening is key for diagnosis  
33 
 
Extraocularmuscle Thickness (normative data) Byrne et al 
 
MR 2.3-4.7mm 
IR 1.6-3.6mm 
LR 2.2-3.8mm 
SR/LPS 3.9-6.8mm 
SUM OF ALL MUSCLES 11.9-16.9mm 
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MEDICAL MANAGEMENT 
 
Step wise evaluation 
Step 1 is to Re-establish euthyroidism  
Step 2 is to stop smoking and conservative managment. 
Step 3 is to determine the activity and severity of disease 
Step 4 is to assess the severity which determines the treatment regime.  
 
 
 
 
 
 
 
 
 
`Active’ disease implies the presence of inflammatory features and 
suggests the potential to respond to anti-inflammatory treatments. 
`Inactive’ disease defines no inflammation, yet residual fibrosis and 
secondary effects may persist. In inactive phase only surgical treatment 
can alter the outcome. Severity describes the degree of functional or 
cosmetic deficit at any stage. It is important to determine the phase for 
35 
formulating an appropriate management because immunomodulatory 
therapy can only be effective while there is active inflammation.  
 
Categorizing the patients as clinically active if CAS SCORE is 4 or 
more and severe ophthalmology based on the parameters like degree of 
proptosis, diplopia, compressive optic neuropathy and corneal 
involvement. Patients in active stage is again categorized into mild, 
moderate and severe disease.  
 
MILD DISEASE:  
Patients are advised to get endocrinologist opinion for control of 
Thyroid Status, advised to stop smoking, topical lubricating eye drops and 
head end elevation of bed. Kept under observation.  
 
MODERATE DISEASE: 
Patients are categorized into active or inactive stage. Those in active 
stage were treated with oral steroids and if not responding low dose 
radiotherapy is given. Patients in inactive stage can be taken up for 
rehabilitative surgery like orbital decompression, strabismus surgery 
followed by lid surgery. 
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SEVERE DISEASE 
 
Patients in severe disease were treated with IV Steroids, Orbital 
radiation with or without steroids, Orbital decompression in case of 
compressive optic neuropathy  
  
PROVEN THERAPIES 
Corticosteroids 
 
Acts as anti-inflammatory and immunosuppressive agent, and 
reduces synthesis and secretion of glycosaminoglycons. Oral/Local/ 
Intravenous administration. Proptosis will less likely to respond and not 
good for long term therapy. Complications include Hypertension, Diabetes 
mellitus, Cataract, glaucoma, infection, peptic ulcer and Osteoporosis. 
 
 
CONTROL OF SEVERITY 
 
Pulse therapy with IV Methylprednisolone 1 gm daily for 3days   at 
6 weekly interval. Response to treatment is monitored for 4-6weeks and 
cycles can be repeated upto 4times.IVMP will cause lymphocytolysis 
when compared to oral steroids which causes suppression of inflammation. 
Retro-bulbar Triamcinolone in the dose of 40mgs/week per orbit for 4 
weeks can be given.  
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ORBITAL RADIATION 
Typical dosage is 20 Gy in 10 Fractions (2 Gy /trt.), lower dose is 
(10 Gy) that is 1 Gy per week for 20 weeks. It should be avoided in mild 
stable disease, in young patients and less effective for proptosis.  But 
improves soft tissue signs, compressive optic neuropathy and extraocular 
motility disorders. 
 
Immunosuppressants (steroid sparing agent) 
Oral Methoterxate: dosage is   7.5mgs/week for 2 
weeks,10mgs/week for 2 weeks and  12.5mgs/week for 5 months, 
Cyclosporine  7.5 mgs/kg/day, Azathioprine,  cyclophosphamide, 
Ciamexon which inhibits expression of HLA DR antigen, are other 
immunosuppessants.  
 
OTHER THERAPIES  
Plasmapheresis, Somatostatin analogues like Octreotid  0.1 mg SC  
tds / 3 months, Lantreotide 40 mgs every other week  for 3 Months, IV 
immunoglobulins, Anti-oxidants like  Selenium  200 mcg/day Rituximab 
(RTX)-Anti-CD20 monoclonal antibody,can cause peripheral B-cell 
depletion and Pentoxyphyline. 
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SURGICAL MANAGEMENT 
 
ORBITAL DECOMPRESSION 
INDICATIONS are failed medical therapy, Progressive 
compressive optic neuropathy and exposure keratopathy, Globe 
subluxation, Pain from tight orbit, Imaging showing evidence of enlarged 
muscles and cosmetic purpose.  
 
HISTORY 
1911 – Dollinger – modification of Kronlein lateral orbitotomy  
1931 – Naffziger – Transfrontal approach 
1936 – Sewall’s – Ethmoidectomy  
1950 – Hirsch & Urbarek – inferior orbitotomy  
1957 – Walsh & Ogura – medial & inferior orbitotomy  
1990 – Kennedy – endoscopic decompression 
Olivari – removal of orbital fat   
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
Techniques described are one-two-three and four wall orbital 
decompression. The floor and medial wall are most commonly 
decompressed. The concept of balanced decompression involves removal 
of lateral and medial wall with sparing the floor with the aim of limiting 
inferomedial globe displacement and consequent motility disturbance and 
diplopia.  
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LATERAL ORBITAL DECOMPRESSION 
 
First wall to decompress.Secondary strabismus is minimal and 2-
4mm of Globe retroplacement but minimally effective in decompression of 
optic nerve. 
 
MEDIAL WALL DECOMPRESSION 
 
Effective in decompression of optic nerve with globe retroplacement 
of 5.5 mm, modified by Ogura. Diplopia  is common following the 
procedure. 
 
TRANSFRONTAL DECOMPRESSION 
 
Neurosurgical approach and effective in B/L optic nerve 
decompression. Frontal lobe signs, pulsating globe, probable meningitis 
can occur. Globe retroplacement upto 3mm. 
 
BONE REMOVAL ORBITAL DECOMPRESSION (BROD) 
 
Indication for BROD is small bony orbital volume with Small 
orbital fat or enlarged muscles with Compressive optic neuropathy. 
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FAT REMOVAL ORBITAL DECOMPRESSION (FROD) 
 
Indication includes large bony volume with large orbital fat volume 
with stretched muscles and for cosmetic purpose. 6cc of fat removal causes 
decrease in proptosis by 4.7mm. 
 
 
STRABISMUS SURGERY: 
 
Diplopia is one of the most functionally disabling aspect of thyroid 
eye disease due to asymmetric restriction of the extraocular muscles. The 
goal of strabismus surgery is to achieve BSV in primary and down gaze. 
The most frequently performed procedure is MR or IR recession. Use of 
adjustable suture to prevent over or under correction. The inferior and 
medial rectus muscles can be recessed safely up to 6–7 mm. Marginal 
myotomies can also help to weaken the restricted muscle. The number of 
operated rectus muscles to no more than three per eye to avoid anterior 
segment ischemia. 
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EYELID SURGERY:  
 
Measurement of eyelid retraction should be stable for up to 6 
months and should follow the squint surgery. In the upper lid, total levator 
muscle recession and partial mullers muscle resection can be done along 
with anchoring the recessed levator muscle is secured with hang back 
sutures anchoring to the conjunctiva, or using scleral graft between the 
recessed muscle and tarsal plate. 
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AIMS AND OBJECTIVES 
 
To   analyze the correlation of clinical parameters and significance 
of objective assessment tools in active Thyroid Eye Disease. 
 
Primary objective: Clinical assessment of Thyroid Eye Disease, to 
identify disease in active phase and start medical management, thereby 
reducing the disease severity. 
 
Secondary objective: To analyze whether the objective tools 
support in aiding the diagnosis of activity in Thyroid Eye Disease.  
 
 
 
 
 
 
 
 
45 
INCLUSION CRITERIA 
 
Clinically diagnosed cases of TED with following features: 
Lid signs 
Soft tissue changes 
Restrictive myopathy 
Bilateral axial proptosis were included in our study. 
Patients in chronic stable phase were excluded from study.  
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MATERIALS AND METHODS 
 
Prospective observational study, conducted at Regional Institute of 
Ophthalmology, Egmore, Chennai from June 2010 till June 2012.Sample 
size was thirty patients in the age group of 20 to 60yrs. 
 
 
METHODS 
Evaluation of patients presenting initially or referred from 
endocrinology department as a known case of  hypo/hyperthyroidism, 
detailed history taking with regard to disease onset,duration and rate of 
progression of the disease, history of  smoking  and history pertaining to 
ocular symptoms like pain, redness, foreignbody sensation, photophobia, 
defective vision, double vision were noted. 
 
Complete ophthalmology workup included 
 
Visual acuity, lid signs, slit lamp examination of anterior segment, 
pupillary reaction, extraocular movements, fundus examination, fields, 
colour vision, diplopia charting, schimers test, Hertels Exophthalmometry, 
differential intraocular  pressure measurement and forced duction test  
were done. 
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Blood examination: Serum level-IL6, HS-CRP, RBS, serological 
test-FreeT3, T4, TSH. Categorizing the patients as clinically active if CAS 
SCORE is 4 or more and severe ophthalmology based on the parameters 
like proptosis, diplopia and optic neuropathy. 
 
Objective disease assessment tools includes 
B scan OTI 1000 wit7.5-10 MHz was used in our study that  
provides topographic information of extraocular muscles using medium 
gain setting  with patient fixating in primary gaze and Longitudinal mode 
with probe placed opposite to the muscle being examined. Internal 
structure and reflectivity was evaluated in anterior 1/3
rd
 -1/2 0f muscle. 
Double peaked sheath spikes indicates that perpendicularity is achieved 
.Tendon sparing muscle enlargement with corresponding low reflectivity is 
observed in A scan. 
 
 
CT SCAN ORBIT-AXIAL AND CORONAL VIEW  
All patients underwent CT orbit for the evidence of Tendon sparing 
extraocular muscle enlargement with apical crowding or fat hypertrophy 
was observed. 
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BIOCHEMICAL PARAMETERS: 
 
 IL-6, HS-CRP, TFT was done and their correlation with activity of 
TED was analysed. The serum samples of patients in moderate and active 
stage are taken and IL-6 and HS-CRP using ELISA was done. The results 
were compared with patients in control group without TED. 
 
The patients diagnosed clinically as TED were categorized as mild, 
moderate and severe activity. Endocrinologist opinion was obtained for all 
patients and treatment of systemic thyroid dysfunction was started. 
Thyroid status was kept under control and advised to stop smoking. 
 
Patients in mild stage were given supportive management like 
topical lubricant eye drops, head end elevation .Patients are followed up 
every 6 months and monitored clinically for disease progression.  
 
Patients in moderately active stage were treated with oral 
Prednisolone 1mg/kg body weight given for 4-6weeks and followed up 
every 2 weeks to assess the disease activity, visual acuity, pupil for RAPD, 
extraocular movements and Hertels exophthalmometry were performed. If 
patients are symptomatically better with resolving signs of activity the 
steroids are continued in the same dosage for 2 weeks and then tapering is 
done. 
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Patients in severe active stage based on subjective ocular symptoms 
and clinical features like soft tissue signs with extraocular movement 
restriction with diplopia, severe proptosis and compressive optic 
neuropathy. Radiological evidence showing apical crowding and A scan 
showing low eye muscle reflectivity were started with IV pulse therapy 
with Methyl prednisolone 1gm diluted in 500ml normal saline infused over 
30 minutes for three days and patients are discharged with oral steroids(40-
60mg).Patients are reviewed every week  for signs of activity, optic nerve 
compression and steroid side effects . 
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OBSERVATION AND DISCUSSION 
 
 In the present study, total number of 30patients in the age group of 
20-60 years with clinical features of active Thyroid Eye Disease were 
examined for the following: 
 
AGE GROUP AT PRESENTATION 
Table -1 
AGE NO OF PATIENTS PERCENTAGE 
20-30YRS 10 33.33 
31-40YRS 8 26.66 
41-50YRS 8 26..66 
51-60YRS 4 13.33 
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The mean age of presentation in our study is 38.86. Most common 
age group being 20-30 years (33.33%). Our study was compared with 
study by Bartelena et al which showed two peak incidence 5
th
 and 7
th
 
decade
41. 
 
10
8 8
4
33.33
26.66 26.66
13.33
20-30YRS 31-40YRS 41-50YRS 51-60YRS
AGE  AT PRESENTATION
NO OF CASES PERCENTAGE
52 
40%
60%
SEX INCIDENCE
MALES FEMALES
SEX DISTRIBUTION 
Table 2 
 
MALES 12(40%) 
FEMALES 18(60%) 
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In our study there were 60% females and 40%males.The female: 
male ratio is 1.5 and the ratio is 0.5 in severe form of disease which was 
correlating to the study conducted by Prummel et al and Haage E et al
42
. 
Our study shows that males have severe form of disease in 66.66% as 
compared to females 33.33%, with the associated smoking as risk factor. It 
is compared with the study by Haage E et al
42.
  which showed Cigarette 
smoking plays an important role in the occurrence of the ophthalmopathy 
and is also associated with a higher degree of disease severity and a lower 
effectiveness of its medical treatment.
42  
Diabetes was present in 6.66% of 
patients in our study which was correlating with the study done by 
Prummel et al
40
 which showed  10%  association with TED and considered 
it to be an significant risk factor. 
 
 
 
 
 
 
 
 
HYPOTHYROID
3.33%
HYPOTHYROID
HYPOTHYROID
HYPERTHYROID
EUTHYROID
 
 
 
 
 
 
 
 
 
In our study the disease pr
Hyperthyroid patients, 
Euthyroid patients and these parameters were comparable with the study 
conducted by Prummel et al.
showed that Graves ophthalmology was more frequent in Hyperthyroidism
(90%),3% in Hypothyroidism and 6% in Euthyroid which was also 
correlating with our study.
HYPER THYROID
EUTHYROID
83.33%
13.33%
THYROID  STATUS
HYPER THYROID EUTHYROID
THYROID STATUS 
Table 3 
 1(3.33) 
 25(83.33) 
 4(13.33) 
ocess was most common in 83.33%
3.33% in Hypothyroid patient and 13.33% in 
40
Another study conducted by Bartley et al 
44
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 in 
 
SYMMETRICAL B/L
21(70%)
 
 
70% patients had bilateral and symmetrical involvement whereas 
30% presented asymmetrically. The study was comparable with the study 
conducted by Bartley et al
 
 
 
ASYMMETRICAL
30%
LATERALITY 
Table 4 
 ASYMMETRICAL B/L
 9(30%) 
13
. 
SYMMETRICAL 
B/L
70%
LATERALITY
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56 
CLINICAL MANIFESTATION 
Table 5 
CLINICAL MANIFESTATION 
NO OF 
PATIENTS 
PERCENTAGE 
LID SIGNS 30 100% 
SOFT TISSUE INFLAMMATION 
WITH CAS >4 
 
OCULAR MOVEMENT 
RESTRICTION 
15 
 
 
 
15 
50% 
 
 
 
50% 
DIPLOPIA 3 10% 
ACTIVE STAGE 
MILD 
MODERATE 
SEVERE 
 
15 
9 
6 
 
50% 
30% 
20% 
OPTIC NERVE COMPRESSION - - 
DIFFERENTIAL IOP >4mm 6 20% 
PROPTOSIS >23mm 6 20% 
IMAGING-CT ORBIT   
EOM ENLARGEMENT 12 40% 
FAT HYPERTROPHY 3 10% 
RISK FACTORS   
SMOKING 9 30% 
DM 2 6.66% 
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30
15 15
3
6 6
9
2100% 50% 50% 10% 20% 20% 30% 6.66%
CLINICAL MANIFESTATION
NO OF CASES PERCENTAGE
 
 
In our study proptosis with lid retraction was most common initial 
presentation .Subjective symptoms like Oppressive Retro orbital feeling 
and pain on eye movement was present in all our patients. (mouritus et 
al1989,bartley et al1996b)
40
. 
 
Objective signs like Conjunctival congestion was present in 73.33% 
and eyelid swelling in 33.33%.Severe proptosis >23mm was present in 
20%.Extraocular movement restriction was present in 50% but 10% 
presented with intermittent diplopia, the differential IOP elevation >4mm 
was found in 20% of these patients which is correlated with the
 
study by 
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Bartley et al 1996b which states that 50% of orbitopathy presents with 
motility restriction .
13
 
 
Soft tissue features were present in 50% of our patients which was 
compared to the study by kendler et al 1993 and Bartley et al 1996b
13
, 
which showed association of soft tissue features in 34-75%. 
 
In our study, 83.33%  of  patients presented  with  6/6 Vision with 
correction, 6/18-6/12 in 13.33%  which was due to cataractous changes 
and 3.33% with vision  <1/60 which was due to associated Retinitis 
pigmentosa and cataract .No patient presented with vision loss due to optic 
nerve compression or corneal involvement in our study. 
 
Patients were categorized as mild by insidious onset,lid lag,lid 
retraction,minimal proptosis,moderately active based on lid signs,soft 
tissue changes,moderate proptosis with intermittent myopathy,imaging 
showing disproportionate proptosis with mild extraocular 
enlargement.severe stage is characterized by rapid onset with predominant 
inflammatory and mass effects,progressive myopathy and compressive 
optic neuropathy, imaging showing evidence of extraocular muscle 
enlargement with apical crowding. 
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CLINICAL ACTIVITY 
 
 
 
 
Patients presenting with clinical activity score >4 was categorized as 
mild stage in 50% of patients, moderately active in 30% and severe disease 
in 20% of patients.  Our study was correlating with the study conducted by 
Bartley et al
13
. 
 
 
 
 
 
50%
30%
20%
ACTIVE STAGE
MILD MODERATE SEVERE
60 
MILD STAGE 
 
MODERATE ACTIVE STAGE 
 
 
MODERATE INACTIVE STAGE 
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SEVERE ACTIVITY 
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LID EDEMA   PERIOBITAL PUFFINESS 
 
 
 
CONJUNCTIVAL CONGESTION                   GOITER 
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EXTRAOCULAR MOVEMENTS RESTRICTION 
     
 
                                    
 
 
 
 
 
                                          
IR MUSCLE
50.00%
B SCAN 
EOM 
THICKENING 
IR MUSCLE 
MR MUSCLE 
LPS-SR 
 
MR
LPS-SR
30.00%
20%
-EOM INVOLVEMENT
IR MUSCLE MR LPS-SR
B SCAN 
Table 6 
 
NO OF PATIENTS PERCENTAGE
15 50% 
9 30% 
6 20.00%
64 
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The B scan was done in longitudinal mode and the extraocular 
muscle thickness was compared with normative data given by Byrene et al. 
Inferior rectus was most frequently involved about 50% followed by 
medial rectus 30% and LPS-SR in 20% of our patients. Our study was 
comparable to the study by EVnagi et al which showed that the inferior 
rectus (93%)  were the most frequently enlarged ,Medial, lateral and 
superior rectuses were enlarged in 59%, 37% and 34% of the orbits 
respectively.
37
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B SCAN 
 
 
TENDON SPARING MR 
MUSCLE ENLARGEMENT 
A SCAN SHOWING LOW 
MUSCLE REFLECTIVITY 
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TENDON SPARING 
MUSCLE ENLARGEMENT 
A SCAN SHOWING LOW 
EYE MUSCLE 
REFLECTIVITY 
68 
MEDIAL RECTUS 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
DOUBLE SPIKE 
INDICATING MUSCLE 
69 
INFERIOR RECTUS 
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40%
10%
CT SCAN FINDING
EOM ENLARGEMENT FAT HYPERTOPHY
CT ORBIT AXIAL AND CORONAL VIEW  
 
 
 
 
 
 
 
 
 
 
 
CT orbit was done for all the patients. Extraocular muscle 
enlargement was present in 40% patients and fat hypertrophy in 10% of 
patients. The fat hypertrophy was more frequent in young individual. Our 
study correlating with the study, Graves Orbitopathy - Current Imaging 
procedures by Berhard Krish et al.
26
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CT ORBIT AXIAL SCAN 
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 CT CORONAL VIEW                             
 
 
 
 
 
 
 
 
 
FAT HYPERTROPHY 
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BIOCHEMICAL ANALYSIS  
 
Biochemical investigation included TFT, IL-6, HS-CRP. The serum 
samples of patients in moderate and severe stage were taken and IL-6 and 
HS-CRP was done using ELISA technique and the results were compared 
with control group without TED.  
 
 
The results were analyzed using ANOVA followed by TURKEY 
HSD test. The P value was significant at 5% level for both IL-6 and HS-
CRP
30
 in severely active patients and was not significant in moderate 
activity group. The mean difference was significant at 0.05 level when 
severe group was compared with control group and not significant when 
moderate group was compared with control group. There was no 
correlation between IL-6 and HS-CRP in the same group. Similar study  
conducted by Prummel et al states that proinflammatory cytokines like IL-
1b, IL-6 and IL-10 are elevated in active TED when compared to inactive 
stage.
38
 Another study by Molnar and Balazs  found that significantly 
increased serum IL-6 was found in Graves Ophthalmopathy and suggested 
that IL-6 may be an important factor in the inflammatory events of Graves’ 
opthalmopathy.
32 
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ANOVA FOLLOWED BY TURKEY HSD TEST 
IL-6 
Activity N Mean 
Standard 
deviation 
P value 
Severe 6 102.5317 150.58581 
 
0.013* 
Moderate 9 2.0311 .41093 
Control 18 15.4328 26.81282 
Total 33 27.6139 72.42253 
 
Note :* denotes significance at 5% level. 
 
 
POST HOC TEST: TURKEY HSD 
 
(I)group (J)group 
Mean 
difference 
Standard error P value 
Severe 
Moderate 100.5006(*) 34.10272 0.016* 
control 34.10272 30.50240 0.021* 
Moderate control -13.4017 26.41586 0.868 
 
*The mean difference is significant at 0.05 level. 
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HS-CRP 
ANOVA 
Activity N Mean 
Standard 
deviation 
P value 
Severe 6 4.9233 4.69085 
 
0.041* 
Moderate 9 3.3444 3.22068 
Control 18 1.7722 .85530 
Total 33 2.7739 2.81818 
 
POST HOC TEST : TURKEY HSD 
(I)group (J)group 
Mean 
difference 
Standard 
error 
P value 
Severe 
Moderate 
1.5789 
 
1.37921 0.495 
control 3.1511(*) 1.23360 0.041* 
Moderate control -1.5722 1.06833 0.319 
 
*The mean difference is significant at 0.05 level. 
CORRELATIONS  
Activity 
Correlation between IL6 and HS -
CRP 
P Value 
Severe -0.399 0.433 
Moderate 0.054 0.891 
Control 0.150 0.553 
 
Not significant 
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PITFALLS  
Though IL-6 and HS-CRP was statistically significant in severe 
disease, the role of these investigation in moderate disease could not be 
assessed because the sample size was small in our study.IL-6 is ELISA 
based analysis which is expensive and needs trained personnel to perform 
the procedure. So it could not be routinely used to screen the patients for 
activity of the disease.   
 
HS-CRP is nonspecific inflammatory marker and again its role in 
moderately active stage could not be assessed in TED. 
 
SUPPORTIVE
50%
MODES OF MANAGEMENT
SUPPORTIVE
Mode of Treatment
Supportive therapy
Oral steroids
IV MP 
 
 
The patients in Mild stage
therapy like topical lubricants and head end elevation.30% of patients 
moderately active stage were treated with oral steroids and 20% of them in 
severe stage with IV Methyl Prednisolone pulse therapy 1gram in 500ml of 
Normal saline for 3 days followed by oral steroids 40
followed weekly and assessed fo
ORAL STEROIDS
IV MP
30%
20%
ORAL STEROIDS IV MP
MANAGEMENT 
Table 7 
 No of Patients 
 15 patients (50%) 
 9 patients (30%) 
6 patients (20%) 
 (50%) were treated with supportive 
-60mg. Patients were 
r disease activity for first 4 weeks. 
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in 
 
Response to treatment
Remission
Exacerbation
 
 
RESPONSE TO TREATMENT
FOLLOW UP 
Table 8 
 No of patients 
 26 (86.66%) 
 4(13.33) 
87%
13%
REMISSION EXACERBATION
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FOLLOW UP 
 
The patients in mild stage who were treated with supportive 
management were followed up every 6 months, moderate and severely 
active patients who were put on either oral or intravenous steroid 
respectively were followed up weekly and biweekly respectively till 4 
weeks to assess the response to treatment. Visualacuity, slit lamp 
examination, differential IOP, fields, colour vision, Hertels 
exophthalmometry, Blood Pressure recording, Random Blood glucose   
and systemic side effects of steroid therapy were monitored. Follow up  
showed remission in 86.66% patients in mild and moderately active stage 
where as 13.33% patients in severe stage  treated with IV 
Methylprednisolone pulse therapy showed exacerbation after  
6months.Those patients were treated with pulse therapy again, followed by 
oral steroids.Remission was attained in all our patients with steroid 
treatment. The study conducted by Thambe K Bargawa concluded that IV 
Methylprednisolone is more effective in moderate and severely active TED 
patients.
39
Eyelid  retraction remained the same in all patients and were 
symptomatically  better, inflammatory signs were reduced and disease 
progression was curtailed. The patients were then followed up monthly for 
6 months and 3monthly thereafter for 1 year. 
80 
RESULTS 
 
 A total of 30 patients in the age group of 20-60years with thyroid 
eye disease were studied over the period of two years for age at 
presentation, sex incidence, presenting clinical features, thyroid status and 
disease activity, associated risk factors. All the patients underwent detailed 
clinical evaluation, supportive investigation was done and treatment was 
recorded. 
 
1. Of the 30 cases examined, most common age group was between 
20-30years (33.33%), females (60%) are most commonly affected 
than males. 
 
2. The disease process was most common in  Hyperthyroid( 83.33%) 
patients as compared to Hypothyroid (3.33%) and Euthyroid status 
(13.33%).Risk factors associated with TED in our study was 
smoking in 30% and Diabetes Mellitus in 6.66% 
 
3. 70% patients had bilateral and symmetrical involvement whereas 
30% presented asymmetrically. 
 
4. Proptosis with lid retraction was most common initial presentation. 
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5. Subjective symptoms like oppressive retro orbital feeling and pain 
on eye movement was present in all our patients. 
 
6. Objective signs like Conjunctival congestion was present in 73.33% 
and   Eyelid swelling in 33.33%.Severe proptosis >23mm was 
present in 20%  and soft tissue features were  present in 50% of our 
patients. 
 
7. Extraocular movement restriction was found in 50% of patients in 
moderate and severely active patient, associated with diplopia only  
in 10% patients, and differential IOP of >4mm difference in about 
20% 0f them. 
 
8. Visual acuity with Snellen chart showed 6/6 in 83.33%, 13.33% 
patients had 6/18-6/12 due to cataractous changes, 3.33% patients 
with vision <1/60 which was due to associated Retinitis Pigmentosa 
and cataract. 
 
9. Patients presenting with clinical activity score >4 were categorized 
as moderately active in 30%, severe disease in 20%, mild stage in 
50% of patients.  
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10. CT ORBIT axial and coronal view showed tendon sparing muscle   
enlargement in 40% of patients and fat hypertrophy in 10% of 
patients. Fat hypertrophy was more common in younger patient. 
 
11. B SCAN- Tendon sparing EOM thickening was found in 
longitudinal mode and the maximum muscle belly was measured, 
corresponding low eye muscle reflectivity was noted in A scan. 
Inferior rectus was most frequently involved (50%) followed by 
medial rectus (30%) and LPS –SR complex in (20%). 
 
12. The patients in moderate and severely active stage, IL-6 and HS-
CRP was done which was compared with control group without 
TED and the results were analyzed using ANOVA followed by 
TURKEY HSD test. The P value was significant at 5% level for 
both IL-6(0.013) and HS-CRP(0.041) in severely active patients and 
was not significant in moderate activity group. The mean difference 
was significant at 0.05 level with the P value of .016 when severe 
group was compared with moderate and control group and not 
significant when moderate group was compared with control group. 
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13. 50% of the patients presented as mild disease who were treated with 
supportive therapy. Moderatly active patients (30%) were treated 
with oral steroids and 20% of the patients in severely active phase 
were treated with pulse Intravenous Methylprednisolone followed 
by oral steroids. 
 
14. Follow up showed remission in 86.66% patients in mild and 
moderately active stage where as 4 patients in severe stage treated 
with iv methylprednisolone pulse therapy showed exacerbation after 
6months.Those patients were treated with pulse therapy again, 
followed by oral steroids. Remission was attained in all our patients 
with steroid treatment, Eyelid retraction remained the same in all 
patients.  
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CONCLUSION 
 
1. Clinical assessment remains the paramount importance in diagnosing 
the activity in Thyroid Eye Disease although controversies do exist in 
clinical evaluation and management.    
 
2. A scan with orbital B scan aids in the diagnosis of thyroid eye disease 
in active stage, which is very economical with relatively short 
examination time and no risk of radiation .Follow up of the patients 
can also be performed easily. 
 
3. IL-6 and HS-CRP was statistically significant at 5% in patients with 
severe disease when compared to control group. The correlation in 
between HS-CRP and IL-6 in all three groups were not significant. 
Though the parameters shows significance for severe disease, its role 
in moderate disease could not be assessed. 
 
4. Identifying the disease activity early and aggressive management with 
systemic steroids in moderately active and severe stage has decreased 
the morbidity associated with the disease.     
85 
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PROFORMA 
 
Name: 
 
Age:                  Sex:            IP No:                DOA:                   DOD: 
 
Address: 
 
Complaints: Onset, duration, rate of progression 
Pain 
Redness and edema of lids and conjunctiva 
Photophobia 
Diplopia 
Forward protrusion of eyes 
Defective vision 
 
Past history: 
Duration of thyroid dysfunction: 
Symptoms pertaining to thyroid disorder: 
 
Hypothyroidism--Weight gain/ Cold intolerance/ Fatigue/ constipation/ 
mennorrhagia/ poor memory/ depression 
 
93 
Hyperthyroidism—weight loss inspite of increased apetite /heat 
intolerance/ restlessness/ diarrhea/ amnorrhoea/ irritability/ tremors and 
palpitation Presence of swelling in the neck. 
 
Treatment history: 
Personal history: Smoking / diabetic/ Hypertention 
 
General Examination:  Nutrition  Pallor 
                                     Cyanosis  Clubbing 
                                     Tremors  Icterus 
 
Pulse rate                          Blood Pressure: 
C.V.S 
R.S 
C.N.S 
 
Thyroid examination: 
 
RE
Ocular examination 
Head posture  
                                          
Lid 
Lid signs 
Position  
Redness 
Swelling 
lagophthalmos 
Orbit 
Proptosis-axial/eccentric                             
Hertels Exophthalmometry
 
 
 
 
 
 
Pulsation                                               
Compressibility/reducibility
Mass/resistance to retropulsion
Valsalva’s maneuver 
Visual acuity by snellens chart
basal 
value
LE
 Facial symmetry 
  RE                           LE 
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95 
Slit lamp examination of anterior segment 
Extraocular movements 
Conjunctiva-congestion/chemosis/cauncle edema 
Cornea –Exposure keratitis  
Stain,sensation,schirmers test 
Anterior chamber 
Pupil 
Lens 
Fundus examination 
Colour vision                Fields 
Differential IOP  
Diplopia charting          FDT 
Investigation 
Complete haemogram,R.B.S,Thyroid function test,IL-6,HS-CRP 
B scan with A scan,CT orbit –Axial and Coronal view. 
Treatment  
Endocrinologist opinion 
Supportive management with topical lubricants  
Oral steroids/I.V pulse therapy with methylprednisolone  
 
FOLLOWUP: 
96 
KEY TO MASTER CHART 
 
T.STA-Thyroid status 
GEN-General Association 
Vn-Visual acuity 
CAS-Clinical Activity Score 
EOM-Extraocular Movement Restriction 
DI ACT-Disease activity 
LS-Lid Signs 
DIP-Diplopia 
D IOP-Differential IOP >4mm 
A/BS-A Scan/B Scan 
CT-CT scan 
IL-IL-6 
HS-HS-CRP 
MAN-Management 
FOL UP-Follow up 
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MASTER CHART 
S. 
No. 
Name AGE SEX T.STA GEN Vn CAS EOM 
DI 
ACT 
LS DIP 
D 
IOP 
A / 
B S 
CT IL HS MAN 
FOL 
UP 
1 ELLAPPAN 57 M HYP S+,DM+ 6/24 PH 6/6 4 PRE SEV PRE PRE PRE Lref E enl 1.8 0.9 IVMP EXA 
2 MURALI 30 M EU NS 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
3 BALAJI 29 M EU S+,DM+ 6/6BE 5 PRE SEV PRE PRE PRE Lref E enl 50 11 IVMP Rem 
4 MANJULA 30 F HYP G+ 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
5 RAJENRAN 50 M HYP S+,DM+ 6/12 PH 6/9 BE 2 ABS MIL PRE PRE ABS NR Eenl 
  
Sup Rem 
6 NASEERABANU 43 F HYPO NS 6/24PH 6/12BE 4 PRE MOD PRE ABS ABS Lref Eenl 1.9 3.3 OS Rem 
7 SUBBULAKSHMI 25 F HYP G+ 
RE-6/6,LE-
6/9PH 6/6 
2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
8 PRABHA 32 F HYP NS BE 6/9PH 6/6 4 PRE MOD PRE ABS ABS Lref Eenl 1.8 11 OS Rem 
9 KAMALA 25 F HYP G+ 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
10 JAYANTHI 43 F HYP G+ 6/6BE 4 PRE MOD PRE ABS ABS Lref Eenl 2 3.7 OS Rem 
11 SABARI 28 F HYP G+ 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
12 AMMUKUTTI 24 F HYP G+ 6/6BE 4 PRE MOD PRE ABS ABS Lref Eenl 1.8 0.2 OS Rem 
13 AMMU 35 F HYP G+ 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
14 SUSHEELA 45 F EU RP HM 4 PRE SEV PRE ABS PRE Lref Eenl 2.2 1.3 IVMP Exa 
15 VADIVEL 32 m HYP s+ 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
16 RAJAN 52 M HYP S+ 6/6BE 4 PRE MOD PRE ABS ABS Lref Eenl 1.4 1.1 OS Rem 
17 YAMUNA 54 F HYP NS 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
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S. 
No. 
Name AGE SEX T.STA GEN Vn CAS EOM DI 
ACT 
LS DIP D 
IOP 
A / 
B S 
CT IL HS MAN FOL 
UP 
18 NITHYA 25 F HYP NS 6/6BE 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
19 
KADHAR MEERA 
SAHIB 
46 M EU S+ BE 6/9PH 6/6 4 PRE SEV PRE ABS PRE Lref Eenl 185 2.6 IVMP Exa 
20 KANAGARAJ 33 M HYP S+ BE 6/9PH 6/6 4 PRE SEV PRE ABS PRE NR FH 374 1.5 IVMP Exa 
21 MURALIDHARAN 43 M HYP S+ BE 6/6 4 PRE MOD PRE ABS ABS Lref FH 1.9 0.7 OS Rem 
22 VANITHA 29 F HYP G+ BE 6/6 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
23 RAMESH 38 M HYP S+ BE 6/6 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
24 VIJAYALAKSHMI 37 F HYP NS BE 6/6 4 PRE MOD PRE ABS ABS Lref Eenl 2.3 5 OS Rem 
25 NEELAVATHI 43 F HYP NS BE 6/9PH 6/6 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
26 PUNITHA 36 F HYP G+ BE 6/24 PH 6/6 4 PRE MOD PRE ABS ABS Lref Eenl 2.8 2.6 OS Rem 
27 KILIAMMAL 60 F HYP NS 
BE 6/36 PH 
6/18 
5 PRE SEV PRE ABS PRE Lref Eenl 2.6 2.2 IVMP Rem 
28 VASIM BISHAH 40 M HYP NS BE 6/6 2 ABS MIL PRE ABS ABS NR Enor 
  
Sup Rem 
29 MOHANKUMAR 28 M HYP NS BE 6/6 4 PRE MOD PRE ABS ABS Lref FH 2.3 2.6 OS Rem 
30 RUKMANI 45 F HYP G+ 
BE 6/36 PH 
6/18 
2 ABS MIL PRE ABS ABS NR Eenl 
  
Sup Rem 
 
 
